1. Disease response and patient-reported outcomes among initiators of ixekizumab
- Author
-
Mona Shahriari, Ryan W. Harrison, Russel Burge, Chen-Yen Lin, William N. Malatestinic, Orin M. Goldblum, Robert R. McLean, Margaux M. Crabtree, Jacqueline O’Brien, Elsie L. Grace, and Mwangi J. Murage
- Subjects
biologics ,ixekizumab ,psoriasis ,treatment ,Dermatology ,RL1-803 - Abstract
Objectives There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes. Methods Adult patients with psoriasis who initiated ixekizumab and completed a 6-month follow-up visit were enrolled from the Corrona Psoriasis Registry. Disease characteristics and outcomes were assessed at ixekizumab initiation. Outcomes included the mean 6-month change in Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator Global Assessment (IGA), and IGA*BSA. Results From baseline to follow-up in all patients (n = 136), means decreased for IGA*BSA (−45.5) and BSA (−12.4), and a higher % achieved an absolute PASI ≤ 5 (84.6%), BSA 0–3 (72.1%), and IGA 0/1 (50.7%). Within stratified groups, means decreased for PASI
- Published
- 2022
- Full Text
- View/download PDF